CLARINET CONTROLLED STUDY OF LANREOTIDE ANTIPROLIFERATIVE RESPONSE IN NET Trademark

Trademark Overview

On Monday, February 15, 2010, a trademark application was filed for CLARINET CONTROLLED STUDY OF LANREOTIDE ANTIPROLIFERATIVE RESPONSE IN NET with the United States Patent and Trademark Office. The USPTO has given the CLARINET CONTROLLED STUDY OF LANREOTIDE ANTIPROLIFERATIVE RESPONSE IN NET trademark a serial number of 79080475. The federal status of this trademark filing is IR CANCELLED - US REGISTRATION CANCELLED as of Sunday, February 16, 2020. This trademark is owned by IPSEN PHARMA S.A.S.. The CLARINET CONTROLLED STUDY OF LANREOTIDE ANTIPROLIFERATIVE RESPONSE IN NET trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Program of medical and scientific studies, namely, scientific investigations for medical purposes; medical and scientific research, namely, conducting clinical trials, studies and analyses, medical and scientific research
clarinet controlled study of lanreotide antiproliferative response in net

General Information

Serial Number79080475
Word MarkCLARINET CONTROLLED STUDY OF LANREOTIDE ANTIPROLIFERATIVE RESPONSE IN NET
Filing DateMonday, February 15, 2010
Status404 - IR CANCELLED - US REGISTRATION CANCELLED
Status DateSunday, February 16, 2020
Registration Number4033261
Registration DateTuesday, October 4, 2011
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 8, 2011

Trademark Statements

Disclaimer with Predetermined Text"CONTROLLED STUDY OF LANREOTIDE ANTIPROLIFERATIVE RESPONSE IN NET"
Goods and ServicesProgram of medical and scientific studies, namely, scientific investigations for medical purposes; medical and scientific research, namely, conducting clinical trials, studies and analyses, medical and scientific research

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, May 11, 2018
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameIPSEN PHARMA S.A.S.
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressFR
Party NameIPSEN PHARMA S.A.S.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressFR
Party NameIPSEN PHARMA S.A.S.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressFR

Trademark Events

Event DateEvent Description
Friday, September 4, 2020NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Friday, September 4, 2020DEATH OF INTERNATIONAL REGISTRATION
Friday, March 8, 2019TOTAL INVALIDATION PROCESSED BY THE IB
Friday, January 25, 2019TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Friday, January 25, 2019INVALIDATION PROCESSED
Friday, January 11, 2019TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Friday, May 11, 2018CANCELLED SECTION 71
Thursday, March 9, 2017TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, March 9, 2017TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, March 1, 2017TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, April 8, 2013FINAL DECISION TRANSACTION PROCESSED BY IB
Friday, May 25, 2012NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Monday, March 12, 2012FINAL DISPOSITION NOTICE SENT TO IB
Monday, March 12, 2012FINAL DISPOSITION PROCESSED
Wednesday, January 4, 2012FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, October 4, 2011REGISTERED-PRINCIPAL REGISTER
Wednesday, September 14, 2011NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, September 14, 2011NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Tuesday, August 23, 2011EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Wednesday, March 9, 2011EXTENSION OF TIME TO OPPOSE RECEIVED
Saturday, February 19, 2011NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Tuesday, February 8, 2011OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 8, 2011PUBLISHED FOR OPPOSITION
Thursday, February 3, 2011NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Thursday, February 3, 2011NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, January 5, 2011LAW OFFICE PUBLICATION REVIEW COMPLETED
Monday, December 20, 2010APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, December 10, 2010TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, December 10, 2010CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, December 10, 2010ASSIGNED TO LIE
Tuesday, November 23, 2010TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, June 26, 2010REFUSAL PROCESSED BY IB
Tuesday, May 25, 2010NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, May 25, 2010REFUSAL PROCESSED BY MPU
Tuesday, May 25, 2010NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, May 24, 2010NON-FINAL ACTION WRITTEN
Tuesday, May 18, 2010ASSIGNED TO EXAMINER
Tuesday, April 13, 2010APPLICATION FILING RECEIPT MAILED
Friday, April 9, 2010NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, April 8, 2010SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

antiproliferative response lanreotide study controlled clarinet scientific medical research namely studies clinical trials analyses investigations program